Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Mannatech Declares First Quarter 2021 Dividend: https://mms.businesswire.com/media/20210511005229/en/877334/5/logo-mannatech-schema.jpg
Mannatech Declares First Quarter 2021 Dividend


Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that

FG Financial Group, Inc. Reports First Quarter 2021 Financial Results
FG Financial Group, Inc. Reports First Quarter 2021 Financial Results


FG Financial Group, Inc. (Nasdaq:FGF) (the “Company”), a reinsurance and investment management holding company focused on opportunistic collateralized and loss capped reinsurance, while allocating

FG Financial Group, Inc. Declares Cash Dividend on Its 8.00% Cumulative Preferred Stock, Series A
FG Financial Group, Inc. Declares Cash Dividend on Its 8.00% Cumulative Preferred Stock, Series A


FG Financial Group, Inc. (Nasdaq:FGF) (the “Company”), a reinsurance and investment management holding company focused on opportunistic collateralized and loss capped reinsurance, while allocating

Fuel Tech Announces Annual Meeting of Stockholders: https://mms.businesswire.com/media/20191104005760/en/446201/5/Fuel_Tech_Logo.jpg
Fuel Tech Announces Annual Meeting of Stockholders


Fuel Tech, Inc. (NASDAQ: FTEK) (or “the Company”), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in

Westwater Resources Announces First Quarter March 31, 2021 Results: https://mms.businesswire.com/media/20210324005153/en/866970/5/4947701_WR_Logo_FA.jpg
Westwater Resources Announces First Quarter March 31, 2021 Results


Westwater Resources, Inc. (NYSE American: WWR), an explorer and developer of U.S. mineral resources essential for batteries for energy storage, today announced its results for the quarter ended

Westwater Resources Strengthens Senior Financial Management Team: https://mms.businesswire.com/media/20210324005153/en/866970/5/4947701_WR_Logo_FA.jpg
Westwater Resources Strengthens Senior Financial Management Team


Westwater Resources, Inc. (NYSE American: WWR), an energy materials company and developer of U.S. mineral resources essential for batteries for energy storage, today announced the appointment of

Fuel Tech Reports 2021 First Quarter Financial Results: https://mms.businesswire.com/media/20191104005760/en/446201/5/Fuel_Tech_Logo.jpg
Fuel Tech Reports 2021 First Quarter Financial Results


Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control, and water treatment in utility and

Aragon Research Includes Qumu in the Globe for Video Conferencing for Third Straight Year: https://mms.businesswire.com/media/20210421005269/en/872964/5/qumu-logo-padded.jpg
Aragon Research Includes Qumu in the Globe for Video Conferencing for Third Straight Year


Qumu Corporation (Nasdaq: QUMU), a leading provider of cloud-based enterprise video technology, today announced it has been positioned by Aragon Research, Inc. in the Contender section of the 2021

ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions: https://mms.businesswire.com/media/20200211005387/en/772640/5/ProtoKinetix_logo_Revised.jpg
ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions


ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced its collaboration with IQVIA (NYSE: IQV) to

Mannatech Reports First Quarter End 2021 Financial Results: https://mms.businesswire.com/media/20210511005229/en/877334/5/logo-mannatech-schema.jpg
Mannatech Reports First Quarter End 2021 Financial Results


Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2021.

Genprex to Participate in Upcoming May Investor Conferences
Genprex to Participate in Upcoming May Investor Conferences


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced that

Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer
Genprex In-Licenses Additional Gene Therapy Technologies for Treatment of Lung Cancer


Genprex, Inc. (“Genprex” or the “Company”) (Nasdaq: GNPX), a clinical-stage gene therapy company focused on developing life-changing technologies for patients with cancer and diabetes, today

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer
Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to

Westwater Resources Announces First Quarter Conference Call and Business Update: https://mms.businesswire.com/media/20210324005153/en/866970/5/4947701_WR_Logo_FA.jpg
Westwater Resources Announces First Quarter Conference Call and Business Update


Westwater Resources, Inc. (NYSE American: WWR), a battery graphite development company, will hold a conference call to discuss its financial results for the first quarter of Fiscal Year 2021 ended

Dover Motorsports, Inc. Announces Appointment of Anastasia Thomas Nardangeli to Its Board of Directors
Dover Motorsports, Inc. Announces Appointment of Anastasia Thomas Nardangeli to Its Board of Directors


Dover Motorsports, Inc. (NYSE Symbol: DVD) announced that the Board of Directors of the Company, at its regularly scheduled quarterly meeting, appointed Anastasia Thomas Nardangeli, as a Director

Dover Motorsports, Inc. Reports Results for the First Quarter Ended March 31, 2021
Dover Motorsports, Inc. Reports Results for the First Quarter Ended March 31, 2021


Dover Motorsports, Inc. (NYSE: DVD) today reported its results for the three months ended March 31, 2021.



The Company historically reports a loss in the first quarter due to the seasonality of

Dover Motorsports, Inc. Declares Semi-Annual Dividend
Dover Motorsports, Inc. Declares Semi-Annual Dividend


Dover Motorsports, Inc. (NYSE: DVD) Board of Directors today declared a semi-annual cash dividend on both classes of common stock of $.04 per share. The dividend will be payable on June 10, 2021 to

Fuel Tech Schedules First Quarter 2021 Financial Results and Conference Call: https://mms.businesswire.com/media/20191104005760/en/446201/5/Fuel_Tech_Logo.jpg
Fuel Tech Schedules First Quarter 2021 Financial Results and Conference Call


Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and

Dover Motorsports, Inc. Announces First Quarter 2021 Earnings Release Date
Dover Motorsports, Inc. Announces First Quarter 2021 Earnings Release Date


Dover Motorsports, Inc. (NYSE: DVD) will report its earnings for the first quarter ended March 31, 2021 on the morning of Thursday, April 29, 2021. Commentary from the Company’s executive officers

ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes: https://mms.businesswire.com/media/20200211005387/en/772640/5/ProtoKinetix_logo_Revised.jpg
ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes


ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP® (PKX-001)

Qumu Introduces AI-Powered Live Captioning for Enterprise Video: https://mms.businesswire.com/media/20210421005269/en/872964/5/qumu-logo-padded.jpg
Qumu Introduces AI-Powered Live Captioning for Enterprise Video


Qumu Corporation (Nasdaq: QUMU), a leading provider of cloud-based enterprise video technology, today announced the development and release of its live captioning capabilities. The new release of

Genprex to Participate in CEO Roadshow Webinar Series
Genprex to Participate in CEO Roadshow Webinar Series


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced

Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes


Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announces today